Download PDF
CC BY 4.0 · Brazilian Journal of Oncology 2018; 14(49): 1-4
DOI: 10.5935/1806-6054.20180007
REVIEW

Year in Review 2018: Lung Cancer

Revisão Ano 2018: Câncer de Pulmão
Vladmir Cláudio Cordeiro de Lima
1   Grupo Brasileiro de Oncologia Torácica, Grupo Brasileiro de Oncologia Torácica - Porto Alegre - RS - Brazil
2   AC Camargo Cancer Center, Departamento de Oncologia - São Paulo - SP - Brazil
,
Clarissa Baldotto
1   Grupo Brasileiro de Oncologia Torácica, Grupo Brasileiro de Oncologia Torácica - Porto Alegre - RS - Brazil
3   Oncologia D'Or, Departamento de Oncologia - Rio de Janeiro - RJ - Brazil
,
Ricardo Mingarini Terra
4   Faculdade de Medicina da Universidade de São Paulo, Instituto do Câncer do Estado de São Paulo - São Paulo - SP - Brazil
,
Livia Fagundes
5   Beneficência Portuguesa de São Paulo, Centro Oncológico - São Paulo - SP - Brazil
,
Ana Gelatti
1   Grupo Brasileiro de Oncologia Torácica, Grupo Brasileiro de Oncologia Torácica - Porto Alegre - RS - Brazil
6   Hospital do Câncer Mãe de Deus, Departamento de Oncologia - Porto Alegre - RS - Brazil
,
William Nassib William Jr
1   Grupo Brasileiro de Oncologia Torácica, Grupo Brasileiro de Oncologia Torácica - Porto Alegre - RS - Brazil
5   Beneficência Portuguesa de São Paulo, Centro Oncológico - São Paulo - SP - Brazil
› Author Affiliations Financial support: none to declare.
› Further Information
   Permissions and Reprints All articles of this category

ABSTRACT

Over the past decade, significant progress has been achieved for clinical management of lung cancers, including screening strategies, use of immunotherapy-based approaches to treat locally advanced and metastatic disease, and development of novel targeted agents for molecularly defined subgroups. In this review, we summarize the studies published/presented in 2018 that form the basis for new standard-of-care management options for lung cancers. These practice-changing studies exemplify the importance of multidisciplinary, evidence-based care to improve outcomes for lung cancer patients.

RESUMO

Durante a última década, foi alcançado um progresso significativo no tratamento clínico de câncer de pulmão, incluindo estratégias de rastreamento, uso de abordagens baseadas em imunoterapia para tratar a doença localmente avançada e a metastática, e o desenvolvimento de novos agentes direcionados para subgrupos definidos molecularmente. Nesta revisão, resumimos os estudos publicados/apresentados em 2018 que formam a base para novas opções de tratamento padrão para o câncer de pulmão. Esses estudos que mudam a prática exemplificam a importância de cuidados multidisciplinares baseados em evidências para melhorar os resultados para pacientes com câncer de pulmão.

Keywords:

Lung Neoplasms - Immunotherapy - Molecular Targeted Therapy

Descritores:

Neoplasias Pulmonares - Imunoterapia - Terapia Molecular Direcionada


Publication History

Received: 28 November 2018

Accepted: 29 November 2018

Article published online:
07 March 2025

© 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • REFERENCES

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    CrossrefPubMedSearch in Google Scholar
  • De Koning H, Van Der Aalst C, Ten Haaf K, Oudkerk M. PL02.05 Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial. J Thorac Oncol 2018; 13 (10) S185
    CrossrefSearch in Google Scholar
  • National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM. et al Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365 (05) 395-409
    CrossrefPubMedSearch in Google Scholar
  • Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R. et al PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377 (20) 1919-1929
    CrossrefPubMedSearch in Google Scholar
  • Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R. et al PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; Sep 25. . Epub ahead of print
    CrossrefPubMedSearch in Google Scholar
  • Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F. et al KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378 (22) 2078-2092
    CrossrefPubMedSearch in Google Scholar
  • Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüs M, Mazières J. et al KEYNOTE-407 Investigators. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018; 379 (21) 2040-2051
    CrossrefPubMedSearch in Google Scholar
  • Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS. et al Brigatinib versus Crizotinib in ALK- Positive Non-Small-Cell Lung Cancer. N Engl J Med 2018; 379 (21) 2027-2039
    CrossrefPubMedSearch in Google Scholar
  • Popat S, Kim HR, Ahn MJ, Yang JC, Han JY, Hochmair MJ. et al Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Ann Oncol 2018; 29 (Suppl 8): mdy424.070
    Search in Google Scholar
  • Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ. et al IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018; Sep 25. Epub ahead of print
    CrossrefPubMedSearch in Google Scholar